Comparing Clomiphene-Primed Ovarian Stimulation and Mid-Luteal GnRH Agonist Protocols: A Cumulative Live Birth Rate and Cost-Effectiveness Analysis in a Single- Center Retrospective Study with Propensity Score Matching

Abstract

The decline in assisted reproductive technology (ART) success among older women, attributed to decreased oocyte quantity and quality, poses a significant challenge. Currently, no consensus exists on the optimal ovarian stimulation protocol for older women undergoing IVF. This retrospective registered cohort study aimed to compare cumulative live birth rates (CLBR), time to live birth (TTLB), and cost-effectiveness in women over 35 years using gonadotropin-releasing hormone agonist (GnRHa) or clomiphene-primed ovarian stimulation (CPOS). We performed propensity score matching (PSM) on 2,871 IVF cycles in women over 35 who received either GnRHa or CPOS protocols, resulting in 375 cycles in each group to compare treatment outcomes. Additionally, a decision tree model was utilized to assess the cost-effectiveness of the two protocols. Following PSM, both groups showed similar baseline characteristics. The CPOS protocol exhibited a higher cycle cancellation rate (13.07% vs 8.00%, p=0.032), yet maintained comparable fertilization and embryo quality. While CLBRs per initial cycle (41.07% vs. 45.33%, p=0.269) and delivery outcomes were similar between the groups after a 24-month follow-up, TTLB was longer in the CPOS group. Notably, the average cost per live birth in the CPOS group was 21.27% less than that in the GnRHa group (￥32,301.42 vs ￥ 39,174.22). In conclusion, for women over 35 undergoing IVF, the CPOS protocol demonstrated similar CLBR to GnRHa but with lower costs, suggesting its potential as a viable and cost-efficient ovarian stimulation option. Clinical trial registration https://www.chictr.org.cn/, identifier [ChiCTR2300076537].